期刊文献+

糖尿病前期患者微量白蛋白尿与胰岛素抵抗相关性研究 被引量:2

原文传递
导出
摘要 目的探讨糖尿病前期胰岛素抵抗与微量白蛋白尿是否具有相关性。方法无糖尿病病史4JD岁以上人群通过口服葡萄糖耐量试验筛查糖尿病前期人群,根据尿微量白蛋白水平分为正常组及增高组,计算其腰围、臀围、体质量指数、胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、胰岛素抵抗指数。结果尿微量白蛋白增高组,胰岛素抵抗明显,两组差异有统计学意义。结论胰岛素抵抗与尿微量白蛋白显著相关,胰岛素抵抗是糖尿病血管病变的基础。
作者 王旭红 赵冬
出处 《中国基层医药》 CAS 2012年第1期78-79,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献7

二级参考文献32

  • 1张晓黎 王桂兰 等.一氧化氮在糖尿病性肾病中的变化及其临床意义[J].中华内分泌代谢杂志,1998,14:18-20.
  • 2Caramofi LM,Fioretto P,Mauer M.The need for early predictors of diabetic nephropathy risk:Is albumin excretion rate sufficient?Diabetes,2000,49(9):1399-1408.
  • 3郭玮,唐文佳,朱文欣,等.不同时段尿微量白蛋白在诊断早期糖尿病肾脏损伤中的应用//2009全国临床生化检验学术会议论文汇编.上海:中华医学会检验分会,2009:50-52.
  • 4Department of Health,UK.National Service Framework for Diabetes.[2009-02-10].http://www.dh.gov.uk/en/Publication-sandstatistics/Publieations/PublicationsPolicyAndGuidance/Browsable,DH_4917725.
  • 5American Diabetes Association.Standards of medical care in diabetes 2007.Diabetes Care,2007,30(Suppl 1):S4-S41.
  • 6McKenna MJ,Feldkanp CS.Microalbuminuria:The key to preventing renal failure in diabetes mellitus.Am Assoc Clin Chem Endocrinol,1989,8(1):5-13.
  • 7McKenna MJ,Amin V,Feldkamp CS,et al.Albumin excretion rate is the preferred way to report microalbuminuria:A study in normal people.J Clin Immunoassay,1987,10(2):151-155.
  • 8Jones CA,Francis ME,Eberhardt MS,et al.Microalbuminuria in the US population:Third National Health and Nutrition Examination Survey.Am J Kidney Dis,2002,39(3):445-459.
  • 9陈新谦,金有豫,汤光.新编药物学.16版.北京:人民卫生出版社,2008:462.
  • 10Parikh CR,Gyamlani GG,Carvounis CP.Screening for microalbuminutia simplified by urine specific gravity.Am J Nephrol,2005,22(4):315-319.

共引文献54

同被引文献29

  • 1周健,贾伟平.2011国际糖尿病联盟餐后血糖管理指南解读[J].中国医学前沿杂志(电子版),2012,4(3):75-78. 被引量:13
  • 2Qin x, Huo Y, l.angman CB, et al. Folic acid therapy and cardio- vascular disease in ESRD or advanced chronic kidney disease : a meta-analysis. Clin J Am Soc Nephro1,2011,22(6 ) :482-488.
  • 3Bai X, Wang X, Xu Q. Endothelial damage and stem cell repair in atherosclerosis. Vascul Pharmacol,2010,52(5-6) :224-229.
  • 4Tousoulis D, Papageorgiou N, Androulakis E, et al. Novel thera- peutic strategies targeting vascular endothelium in essential hyper- tension. Expert Opin Investig Drugs,2010,19( 11 ) :1395-1412.
  • 5Probstfield JL, OBrien KD. Progression of cardiovascular damage : the role of renin-angiotensin system blockade. Am J Cardiol, 2010,105 ( 1 Suppl) : 10A-20A.
  • 6Rius C,Abu-Taha M, Hermenegildo C, et al. Trans-but not cis-res- veratrol impairs angiotensin-ll-mediated vascular inflammation through inhibition of NF-KB activation and peroxisome proliferator- activated receptor-gamma upregulation. J Immunol,2010,185 (6) : 3718-3727.
  • 7Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc I-Iypertens ,2010,4 ( 1 ) :42-50.
  • 8Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag, 2009,5 ( 7 ) : 713-722.
  • 9Heinz J, Kropf S, Domrse U, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation, 2010, 121 (12) :1432-1438.
  • 10黄昭瑄,黄昭穗,李燕娃,尹秀英.阿卡波糖与混合胰岛素联合应用的临床意义[J].临床军医杂志,2008,36(3):390-392. 被引量:4

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部